Summary & Overview
Bronchitis and Asthma without CC/MCC: Inpatient Reimbursement Overview
203 encompasses bronchitis and asthma admissions without CCs or MCCs; it addresses straightforward respiratory exacerbations and infectious bronchitis. Understanding this Diagnosis-Related Group is important for inpatient reimbursement since the DRG assignment influences Medicare payment weight and hospital revenue for these respiratory cases.
DRG 203 Overview
Diagnosis-Related Group 203 covers inpatient admissions for bronchitis and asthma without a Complication or Comorbidity (CC) or Major Complication or Comorbidity (MCC). This DRG typically applies to cases with acute bronchospasm, acute exacerbations of asthma, or infectious bronchitis that do not generate additional complicating diagnoses. It matters for Medicare payment because the absence of CCs/MCCs places these cases in a lower-weighted DRG, affecting reimbursement levels for hospitals.
National Payment Rates
Mean payer rates for Bronchitis and Asthma without Complication or Comorbidity range roughly from $4,633.08 for Medicare to $11,366.64 for Cigna, with a broad spread across commercial plans. The largest gaps appear between Medicare and the highest commercial means, reflecting substantial variation by payer. See the table and chart below for payer-level detail.
The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for Diagnosis-Related Group .
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.